Naoya Nishioka; Tae Hata; Tadaaki Yamada; Yasuhiro Goto; Akihiko Amano; Yoshiki Negi; Satoshi Watanabe; Naoki Furuya; Tomohiro Oba; Tatsuki Ikoma; Akira Nakao; Keiko Tanimura; Hirokazu Taniguchi; Akihiro Yoshimura; Tomoya Fukui; Daiki Murata; Kyoichi Kaira; Shinsuke Shiotsu; Makoto Hibino; Asuka Okada; Yusuke Chihara; Hayato Kawachi; Takashi Kijima; Koichi Takayama

doi:10.4143/crt.2024.748

Articles

Page Path: HOME > Cancer Res Treat > Volume 57(2); 2025 > Article

Original Article Lung and Thoracic cancer Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non–Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study: Naoya Nishioka¹, Tae Hata¹, Tadaaki Yamada^1,, Yasuhiro Goto², Akihiko Amano³, Yoshiki Negi⁴, Satoshi Watanabe⁵, Naoki Furuya⁶, Tomohiro Oba⁷, Tatsuki Ikoma⁸, Akira Nakao⁹, Keiko Tanimura¹⁰, Hirokazu Taniguchi¹¹, Akihiro Yoshimura¹², Tomoya Fukui¹³, Daiki Murata¹⁴, Kyoichi Kaira¹⁵, Shinsuke Shiotsu¹⁶, Makoto Hibino¹⁷, Asuka Okada¹⁸, Yusuke Chihara¹⁹, Hayato Kawachi¹, Takashi Kijima⁴, Koichi Takayama¹; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2025;57(2):412-421.
DOI: https://doi.org/10.4143/crt.2024.748
Published online: October 25, 2024

¹Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

²Department of Respiratory Medicine, Fujita Health University School of Medicine, Aichi, Japan

³Department of Respiratory Medicine, Kurashiki Central Hospital, Okayama, Japan

⁴Department of Respiratory Medicine and Hematology, School of Medicine, Hyogo Medical University, Hyogo, Japan

⁵Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

⁶Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan

⁷Department of Respiratory Medicine, Saitama Red Cross Hospital, Saitama, Japan

⁸Department of Thoracic Oncology, Kansai Medical University, Osaka, Japan

⁹Department of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan

¹⁰Department of Medical Oncology, Fukuchiyama City Hospital, Kyoto, Japan

¹¹Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

¹²Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan

¹³Department of Respiratory Medicine, Shonan Kamakura General Hospital, Kanagawa, Japan

¹⁴Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan

¹⁵Department of Respiratory Medicine, Inter- national Medical Center, Saitama Medical University, Saitama, Japan

¹⁶Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan

¹⁷Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital, Kanagawa, Japan

¹⁸Department of Respiratory Medicine, Saiseikai Suita Hospital, Osaka, Japan

¹⁹Department of Respiratory Medicine, Uji-Tokushukai Medical Center, Kyoto, Japan

Correspondence: Tadaaki Yamada, Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan
Tel: 81-752515111 E-mail: tayamada@koto.kpu-m.ac.jp

• Received: August 7, 2024 • Accepted: October 24, 2024

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

2,397 Views
286 Download

prev next

Full Article

Download PDF

Abstract

Purpose
Thyroid transcription factor 1 (TTF-1) expression is a useful predictor of treatment efficacy in advanced non-squamous non–small cell lung cancer (NSCLC). This study aimed to evaluate whether TTF-1 could predict the effectiveness of chemotherapy versus chemoimmunotherapy in patients with non-squamous NSCLC with programmed death ligand-1 (PD-L1) expression between 1% and 49%.
Materials and Methods
We conducted a retrospective study of patients with NSCLC who were treated with chemotherapy or chemoimmunotherapy between March 2016 and May 2023. The patients had histologically confirmed NSCLC, stage III-IV or postoperative recurrence, TTF-1 measurements, and PD-L1 expression levels between 1% and 49%. Clinical data were analyzed to evaluate the effect of TTF-1 expression on treatment efficacy.
Results
This study included 283 of 624 patients. TTF-1–positive patients showed longer progression-free survival (PFS) and overall survival (OS) (PFS: 6.4 months [95% confidence interval (CI), 5.0 to 9.4] vs. 4.1 months [95% CI, 2.7 to 6.1], p=0.03; OS: 17.9 months [95% CI, 15.2 to 28.1] vs. 9.4 months [95% CI, 6.3 to 17.0], p < 0.01) in the chemotherapy cohorts (n=93). In the chemoimmunotherapy cohort (n=190), there was no significant difference in PFS and OS between TTF-1–positive and –negative groups (PFS: 7.6 months [95% CI, 6.4 to 11.0] vs. 6.0 months [95% CI, 3.6 to 12.6], p=0.59; OS: 25.0 months [95% CI, 18.0 to 49.2] vs. 21.3 months [95% CI, 9.8 to 28.8], p=0.09).
Conclusion
In patients with NSCLC with PD-L1 expression between 1% and 49%, TTF-1 expression was a predictor of chemotherapeutic, but not chemoimmunotherapeutic, efficacy.
Key words: Thyroid transcription factor 1, PD-L1, Non-small-cell lung carcinoma, Chemoimmunotherapy, Chemotherapy

Introduction

Thyroid transcription factor 1 (TTF-1) is a key immunohistochemical marker for diagnosing lung cancer, distinguishing lung and thyroid adenocarcinomas from cancers of other sites, and differentiating lung adenocarcinomas and small-cell lung cancer from squamous cell carcinoma [1]. TTF-1 expression is linked to approximately 30% of fatal lung adenocarcinoma cases [2-4]. The variation in TTF-1 expression may be related to the degree of tumor differentiation within the same tumor category [5]. TTF-1 expression influences treatment response and prognosis in patients with non-squamous non–small cell lung cancer (NSCLC) [6-9]. TTF-1 is also a useful prognostic factor for the risk of postoperative recurrence [10-12] and a predictor of response to cytotoxic chemotherapy in patients with advanced non-squamous NSCLC [6,9,13,14].

Since the advent of immunotherapy, the survival rate of patients with advanced NSCLC has increased significantly. Chemoimmunotherapy, which combines chemotherapy and immunotherapy, has become the first-line treatment for patients with advanced NSCLC. Therefore, predicting the efficacy of this combination therapy is crucial. Although intratumoral programmed death ligand-1 (PD-L1) expression is a robust predictor of response to immunotherapy and chemoimmunotherapy and is employed in clinical practice, it is not comprehensive. This study aimed to evaluate whether tumor expression of TTF-1, a known predictor of chemotherapy response, could also predict the efficacy of chemoimmunotherapy in patients with advanced lung cancer and PD-L1 expression ranging between 1% and 49%.

Materials and Methods

1. Patients and study design

We conducted a retrospective study of patients with NSCLC who received chemotherapy or chemoimmunotherapy at 19 institutions in Japan between March 2016 and May 2023. We included patients with (1) histologically diagnosed NSCLC; (2) histologically certified stage III-IV according to TNM staging (American Joint Committee on Cancer 8th edition) or postoperative recurrence; (3) available TTF-1 measurements; and (4) PD-L1 expression between 1% and 49%. Subsequently, we excluded the following patients: (1) those histologically diagnosed with squamous cell carcinoma, (2) those not evaluated for TTF-1 expression in tumors, and (3) those with driver mutations. Clinical data were collected from the electronic medical records. PD-L1 scores were analyzed using PD-L1 immunohistochemistry with 22C3 pharmDx antibody (clone 22C3, Dako North America, Inc.), and TTF-1 was analyzed using mouse 84 monoclonal anti-TTF-1 antibody clone 8G7G3/1, mouse monoclonal anti-TTF-1 antibody clone 85 SPT24, and rabbit monoclonal anti– TTF-1 antibody clone SP141.

2. Assessment outcome

We examined the effect of TTF-1 expression on treatment efficacy in patients receiving chemotherapy and chemoimmunotherapy, including the effect of pemetrexed-containing regimens in TTF-1–negative and TTF-1–positive patients. Progression-free survival (PFS) was defined as the duration from the date of treatment initiation to the date of tumor progression or death. Overall survival (OS) was defined as the duration from the date of initiation of first-line treatment to the date of all-cause death. The follow-up cutoff date was January 5, 2024, and the median follow-up duration was 21.3 months.

3. Statistical analysis

Binomial variables were analyzed using Fisher’s exact test. Differences in continuous variables between the two groups were assessed using the Mann-Whitney U test. PFS and OS were evaluated using the Kaplan-Meier method and compared using the log-rank test. Cox proportional hazard models were used to assess predictive and prognostic factors for PFS and OS. All analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan) and the R graphical user interface (R Foundation for Statistical Computing), with statistical significance set at p < 0.05 [15].

Results

1. Patient characteristics

We first identified 624 patients with advanced or recurrent NSCLC with PD-L1 expression between 1% and 49% who received chemotherapy or chemoimmunotherapy between August 2014 and June 2023 at 19 institutions in Japan. Of these, 295 patients without TTF-1 expression evaluation were excluded, followed by the exclusion of 45 patients with actionable driver mutations, such as epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK), as well as one patient who received pembrolizumab monotherapy. Finally, two hundred eighty-three patients were included in the study (S1 Fig.). The patient characteristics are presented in Tables 1 and 2. The median age of the patients in the chemotherapy cohort (n=93) was 68 years (range, 39 to 81 years). Most patients were male (76.3%) and had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1 (88.2%). Additionally, most tumors were adenocarcinomas (73.1%) or initial stage IV (73.1%), with the majority having PD-L1 expression of 1% or more but less than 25% (68.8%). We classified patients into TTF-1–positive or negative groups, and the TTF-1–positive group had a significantly higher percentage of adenocarcinomas (83.0% vs. 60.0%, p=0.02). The median patient age in the chemoimmunotherapy cohort (n=190) was 69 years (range, 36 to 85 years). Similar to the chemotherapy cohort, most patients were male (75.6%) and had an ECOG PS of 0-1 (92.1%). Most tumors were adenocarcinomas (93.7%) or initial stage IV tumors (84.2%), with the majority having PD-L1 expression of 1% or more but less than 25% (72.1%). In both the chemotherapy and chemoimmunotherapy cohorts, the TTF-1–positive group had a significantly lower proportion of non-adenocarcinoma NSCLC than the TTF-1–negative group (chemotherapy cohort: 17.0% vs. 40.0%, p=0.02, chemoimmunotherapy cohort: 6.3% vs. 38.1%, p < 0.01).

2. Impact of TTF-1 expression on the efficacy of chemotherapy

In the chemotherapy cohort, the median follow-up period was 16.4 months (range, 12.6 to 20.8 months), and 81 of 93 patients (87.1%) experienced progressive disease. Regarding PFS, the TTF-1–negative group had a significantly shorter PFS than the TTF-1–positive group (4.1 months [95% confidence interval (CI), 2.7 to 6.1] vs. 6.4 months [95% CI, 5.0 to 9.4], p=0.03) (Fig. 1A). Multivariate analysis revealed that TTF-1 expression (adjusted hazard ratio [HR], 0.58; 95% CI, 0.36 to 0.93; p=0.02) and ECOG PS (adjusted HR, 0.41; 95% CI, 0.19 to 0.88; p=0.02) were independent predictive factors for PFS (Table 3). Similarly, in terms of OS, the TTF-1–negative group had significantly shorter OS than that of the positive group (9.4 months [95% CI, 6.3 to 17.0] vs. 17.9 months [95% CI, 15.2 to 28.1], p < 0.01) (Fig. 1B). In the multivariate analysis of OS, TTF-1 expression (adjusted HR, 0.61; 95% CI, 0.37 to 1.03; p=0.06) and histology (adjusted HR, 0.60; 95% CI, 0.35 to 1.04; p= 0.07) were identified as important factors. However, they were not statistically significant (Table 3).

3. Impact of TTF-1 expression on the efficacy of chemoimmunotherapy

In the chemoimmunotherapy cohort, the median follow-up period was 24.1 months (range, 18.0 to 28.8 months), and 139 of 190 patients (73.2%) experienced progressive disease. Regarding PFS, there were no significant differences between the TTF-1–negative and positive groups (6.0 months [95% CI, 3.6 to 12.6] vs. 7.6 months [95% CI, 6.4 to 11.1], p=0.59) (Fig. 1C). In the multivariate analysis of PFS, ECOG PS (adjusted HR, 0.51; 95% CI, 0.26 to 0.98; p=0.04) was an independent predictor of PFS, while TTF-1 expression did not show significance (adjusted HR, 0.86; 95% CI, 0.57 to 1.30; p=0.48) (Table 4). Regarding OS, there was a discernible tendency towards enhanced performance in the chemoimmunotherapy cohort. However, no discernible discrepancy was observed between the TTF-1–negative and positive groups (21.3 months [95% CI, 9.8 to 28.8] vs. 25.0 months [95% CI, 18.0 to 49.2], p=0.09) (Fig. 1D). In the multivariate analysis of OS, TTF-1 was also not a prognostic factor (adjusted HR, 0.79; 95% CI, 0.50 to 1.25; p=0.31) (Table 4).

4. Comparison of OS between pemetrexed-based and non-pemetrexed–based regimens within the chemotherapy and chemoimmunotherapy cohorts, stratified by TTF-1 expression status

The chemotherapy and chemoimmunotherapy cohorts were divided into TTF-1–positive and negative groups, and chemotherapy in each group was classified as follows to evaluate OS: pemetrexed-based chemotherapy group (PC group)/chemoimmunotherapy group (CI with PEM group) and non-pemetrexed–based chemotherapy group (non-PC group)/chemoimmunotherapy group (CI without PEM group). In the chemotherapy cohort, the OS was significantly longer in the PC group than in the non-PC group within the TTF-1–positive group (23.9 vs. 16.4 months, p=0.02) (Fig. 2A). However, in the TTF-1–negative group, there was no significant difference between the two groups (9.4 months vs. 10.0 months, p=0.42) (Fig. 2C). In the chemoimmunotherapy cohort, regardless of TTF-1 expression, there was no significant difference in OS between the CI with and without PEM groups (TTF-1–positive: 27.5 months vs. 22.6 months, p=0.25 [Fig. 2B], TTF-1–negative: 21.3 months vs. 18.4 months, p=0.53 [Fig. 2D]).

5. Comparison of treatment efficacy between chemoimmunotherapy and chemotherapy stratified by TTF-1 expression

We compared the efficacy of chemoimmunotherapy and chemotherapy stratified by TTF-1 expression. In both TTF-1–positive and negative groups, PFS tended to be longer with chemoimmunotherapy than with chemotherapy (TTF-1–positive: 7.6 months vs. 6.4 months, p=0.054 [S2A Fig.]; TTF-1–negative: 6.0 months vs. 4.1 months, p=0.007 [S2C Fig.]). However, for OS, no significant difference was observed between the two treatment modalities in either group (TTF-1–positive: 25.0 months vs. 17.9 months, p=0.28 [S2B Fig.]; TTF-1–negative: 21.3 months vs. 9.4 months, p=0.13 [S2D Fig.]).

Discussion

This is the most extensive study to evaluate the influence of TTF-1 expression on the therapeutic effectiveness of chemoimmunotherapy and chemotherapy in patients with NSCLC with PD-L1 levels between 1 and 49%. Therefore, the results suggest that while TTF-1 was a prognostic factor in the chemotherapy cohort, it was not a prognostic factor in the chemoimmunotherapy cohort, indicating that immunotherapy may compensate for the prognosis of TTF-1–negative NSCLC.

Prior to the clinical adoption of immunotherapy, previous studies consistently reported that TTF-1 expression influenced the therapeutic efficacy and prognosis of cytotoxic chemotherapy [6,7,9,14,16]. Among the groups treated with cytotoxic chemotherapy in this study, the TTF-1–positive group tended to have a longer PFS and OS than the TTF-1–negative group. Multivariate analysis also suggested that TTF-1 could serve as an independent predictor of PFS and OS, as shown in previous studies. Several factors contribute to the worse prognosis of patients with TTF-1–negative NSCLC compared to those who are TTF-1–positive. Among these, we focused on the relationship between TTF-1 expression and epithelial-mesenchymal transition (EMT). EMT has been reported to contribute to resistance to treatment, including cytotoxic anticancer agents, cancer progression, and malignancy [17]. Saito et al. [18] demonstrated that, in NSCLC, TTF-1 suppresses EMT by inhibiting the expression of Snail and Slug, which are downstream molecules of transforming growth factor β (TGF-β). Furthermore, TGF-β signaling has been suggested to suppress TTF-1 expression. Based on these preclinical findings, it is expected that patients with TTF-1–negative NSCLC may exhibit lower treatment responsiveness to chemotherapy and worse prognosis due to EMT induction.

Since the clinical adoption of immunotherapy, the effect of TTF-1 expression on patient outcomes in NSCLC treated with immunotherapy or chemotherapy remains unclear. This study found that among patients with NSCLC and PD-L1 expression between 1% and 49%, TTF-1 did not affect the treatment response or prognosis in the chemoimmunotherapy group. However, recent studies suggest that TTF-1 might predict therapeutic response to chemotherapy and conventional chemotherapy [19-24]. Our previous study found that TTF-1 was a predictor of chemoimmunotherapy, which contradicts the results of this study [25]. These conflicting findings may stem from various factors; however, the association between TTF-1 and PD-L1 expression is particularly significant. Our previous study reported that significantly more patients in the TTF-1–negative NSCLC group had low or negative PD-L1 expression than those in the TTF-1–positive group [25]. As a result, TTF-1–negative patients are less likely to benefit from the therapeutic effects of programmed death-1 (PD-1)/PD-L1 inhibitors, which may have resulted in inferior PFS and OS. Several other studies have also reported this association between PD-L1 and TTF-1 [26,27]. Therefore, in this study, limiting patients with NSCLC to those with a PD-L1 expression rate of 1% to 49% would eliminate the imbalance in PD-L1 expression between the TTF-1–positive and negative groups, suggesting that TTF-1 expression does not affect treatment efficacy in chemoimmunotherapy. Supporting this hypothesis, our previous study showed no significant difference in treatment efficacy between patients who are TTF-1–positive and those who are negative, even in patients with NSCLC with PD-L1 expression ≥ 50%, whether they received PD-1/PD-L1 monotherapy or chemoimmunotherapy [28]. Therefore, it can be inferred that the influence of TTF-1 expression is minimal, at least during periods when the effects of PD-1/PD-L1 inhibitors are more pronounced.

We compared survival in pemetrexed-based and non-pemetrexed-based regimen groups stratified by TTF-1 expression in both chemotherapy and chemoimmunotherapy cohorts. The chemotherapy cohort indicated that OS may vary by regimen depending on TTF-1 expression, whereas the chemoimmunotherapy cohort showed no significant difference in OS according to regimen type, regardless of TTF-1 expression [6,7,9,14,16]. This study showed that OS was not affected by regimen type in the chemoimmunotherapy cohort, regardless of TTF-1 expression. OS tends to increase with chemotherapy, and the impact of post-treatment chemotherapy is expected to be significant. Additionally, the small sample size in this study may have contributed to these results. Therefore, further large-scale studies are warranted.

This study has some limitations. First, although this was the largest cohort study of this population, it was a retrospective Japanese study with a relatively small sample size. Specifically, comparing the treatment regimens for each TTF-1 expression group, especially chemoimmunotherapy, involved a small number of patients. Second, the selection of treatment regimens may vary owing to factors other than TTF-1, potentially influencing treatment efficacy in each population. Third, this study did not have information on driver gene abnormalities in NSCLC other than EGFR and ALK, which may indicate the presence of other mutations in the study population. Consequently, it cannot be ruled out that these unassessed abnormalities may have influenced the study results. Finally, we did not collect data on tumor differentiation in this study, and it is possible that differences in differentiation could have influenced treatment outcomes.

In conclusion, in patients with NSCLC with PD-L1 expression between 1% and 49%, TTF-1 expression was a predictor of cytotoxic chemotherapeutic but not chemoimmunotherapeutic efficacy. The addition of immunotherapy may attenuate the adverse effects of TTF-1 expression on the therapeutic effects of chemoimmunotherapy. Further prospective studies with larger sample sizes are required to verify these findings.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).

crt-2024-748_S1_Fig.pdf

crt-2024-748_S2_Fig.pdf

NOTES

Ethical Statement

This study was conducted in compliance with the principles of the Declaration of Helsinki. This study complied with the Declaration of Helsinki and followed protocols approved by the Ethics Committee of the Kyoto Prefectural University of Medicine (approval No. ERB-C-2934), covering all participating centers through a centralized review process. Informed consent for the use of personal medical data was obtained using the opt-out method as described in the disclosure document.

Author Contributions

Conceived and designed the analysis: Nishioka N, Yamada T.

Collected the data: Nishioka N, Hata T, Goto Y, Amano A, Negi Y, Watanabe S, Furuya N, Oba T, Ikoma T, Nakao A, Tanimura K, Taniguchi H, Yoshimura A, Fukui T, Murata D, Kaira K, Shiotsu S, Hibino M, Okada A, Chihara Y, Kawachi H.

Contributed data or analysis tools: Nishioka N, Yamada T.

Performed the analysis: Nishioka N, Yamada T.

Wrote the paper: Nishioka N, Yamada T.

Supervision: Kijima T, Takayama K.

Conflict of Interest

N. Nishioka received personal fees from Chugai Pharmaceutical Co. Ltd., AstraZeneca KK., Eli Lilly Japan KK, and MSD KK, outside the purview of the submitted work. Tadaaki Yamada received research grants from Ono Pharmaceutical, Janssen, AstraZeneca, and Takeda Pharmaceutical and has received speaking honoraria from Eli Lilly and Chugai-Roshe outside the purview of the submitted work. Satoshi Watanabe received grants from Boehringer Ingelheim and Nippon Kayaku and has received honoraria for speakers’ bureaus from Lilly, Novartis Pharma, Chugai Pharma Bristol-Myers, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Nippon Kayaku, Kyowa Kirin, Merck, Takeda Pharmaceutical, Celltrion, and AstraZeneca outside the purview of the submitted work. Hirokazu Taniguchi has received lecture fees from AstraZeneca and Chugai Pharma. Tomoya Fukui received personal fees from AstraZeneca K.K., Boehringer-Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan KK, Nippon Kayaku Co. Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., and Pfizer Japan Inc., outside the scope of the submitted work. Kyoichi Kaira has received speaker honorariums from Ono Pharmaceutical Company, Chugai Pharmaceutical, Bristol-Myers Company, Boehringer Ingelheim, and AstraZeneca, and research grants from AstraZeneca. Asuka Okada has received personal fees from Chugai-Roshe, Kyowa Kirin, MSD KK, AstraZeneca, Takeda Pharmaceutical, Boehringer Ingelheim, Eli Lilly, Japan, Nippon Kayaku, and Bristol-Myers Squibb outside the purview of the submitted work. Hayato Kawachi received personal fees from Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., AstraZeneca KK, Taiho Pharmaceutical Co. Ltd., Eli Lilly Japan KK, and MSD KK, outside the purview of the submitted work. Takashi Kijima received personal fees from Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd., and MSD KK, outside the purview of the submitted work. Koichi Takayama received research grants from Chugai Pharmaceutical Co. Ltd. and Ono Pharmaceutical and personal fees from AstraZeneca, Chugai Pharmaceutical Co. Ltd., MSD-Merck, Eli Lilly, Boehringer Ingelheim, and Daiichi-Sankyo outside the purview of the submitted work. The other authors declare no potential conflicts of interest.

Fig. 1.

Comparison of treatment efficacy between thyroid transcription factor-1 (TTF-1)–positive and negative groups in the chemotherapy and chemoimmunotherapy cohorts. Kaplan-Meier curves for progression-free survival (PFS) (A) and overall survival (OS) (B) in the chemotherapy cohorts. Kaplan-Meier curves for PFS (C) and OS (D) in the chemoimmunotherapy cohort. CI, confidence interval.

Fig. 2.

Comparison of overall survival (OS) between pemetrexed (PEM)-based and non-PEM–based regimens within the chemotherapy and chemoimmunotherapy cohorts stratified by thyroid transcription factor-1 (TTF-1) expression status. We compared the OS between the PEM-based and non-PEM–based regimen groups in the chemotherapy and chemotherapy cohorts stratified by TTF-1 expression status. Kaplan-Meier curves are shown for the chemotherapy (A) and chemoimmunotherapy (B) groups in the TTF-1–positive population and for the chemotherapy (C) and chemoimmunotherapy (D) groups in the TTF-1–negative population. CI, confidence interval.

Table 1.

Patient characteristics: chemotherapy cohort

Characteristic	Total (n=93)	TTF-1–negative (n=40)	TTF-1–positive (n=53)	p-value
Age (yr)	68 (39-81)	70.5 (45-81)	66 (39-79)	0.06
Sex
Male	71 (76.3)	32 (80.0)	39 (73.6)	0.62
Female	22 (23.7)	8 (20.0)	14 (26.4)
ECOG PS
0-1	82 (88.2)	34 (85.0)	48 (90.6)	0.52
≥ 2	11 (11.8)	6 (15.0)	5 (9.4)
Stage
IIIB	4 (4.3)	1 (2.5)	3 (5.7)	0.24
IIIC	6 (6.5)	4 (10.0)	2 (3.8)
IVA	35 (37.6)	13 (32.5)	22 (41.5)
IVB	32 (34.4)	17 (42.5)	15 (28.2)
IVC	1 (1.1)	1 (2.5)	0
Postoperative recurrence	15 (16.1)	4 (10.0)	11 (20.8)
Histology
Adeno	68 (73.1)	24 (60.0)	44 (83.0)	0.02
Others	25 (26.9)	16 (40.0)	9 (17.0)
LCNEC	4 (4.3)	4 (10.0)	0
Pleomorphic carcinoma	0	0	0
NOS	21 (22.6)	12 (30.0)	9 (17.0)
PD-L1 TPS (%)
1-25	29 (31.2)	12 (30.0)	17 (32.1)	0.82
26-49	64 (68.8)	28 (72.0)	36 (67.9)
Liver metastasis	11 (11.8)	8 (20.0)	3 (5.7)	0.05
Brain metastasis	15 (16.1)	7 (17.5)	8 (15.1)	0.88
Treatment regimen
CBDCA/PTX or nab-PTX	31 (33.3)	17 (42.5)	14 (26.4)
CDDP or CBDCA/PTX/BEV	1 (1.1)	1 (2.5)	0
CDDP or CBDCA/PEM	30 (32.3)	11 (27.5)	19 (35.8)
CDDP or CBDCA/PEM/BEV	24 (25.8)	8 (20.0)	16 (30.2)
CDDP or CBDCA/S-1	6 (6.4)	2 (5.0)	4 (7.5)
CDDP/DTX	1 (1.1)	1 (2.5)	0

Values are presented as median (range) or number (%). BEV, bevacizumab; CBDCA, carboplatin; CDDP, cisplatin; DTX, docetaxel; ECOG PS, Eastern Cooperative Oncology Group performance status; LCNEC, large cell neuroendocrine carcinoma; NOS, not otherwise specified; PD-L1, programmed cell death ligand 1; PEM, pemetrexed; PTX, paclitaxel; TPS, tumor proportion score; TTF-1, thyroid transcription factor-1.

Table 2.

Patient characteristics: chemoimmunotherapy cohort

Characteristic	Total (n=190)	TTF-1–negative (n=63)	TTF-1–positive (n=127)	p-value
Age (yr)	69 (36-85)	69 (37-78)	68 (36-85)	0.64
Sex
Male	151 (79.5)	55 (87.3)	96 (75.6)	0.09
Female	39 (20.5)	8 (12.7)	31 (24.4)
ECOG PS
0-1	178 (93.7)	61 (96.8)	117 (92.1)	0.34
≥ 2	12 (6.3)	2 (3.2)	10 (7.9)
Stage
IIIB	4 (2.1)	3 (4.8)	1 (0.8)	0.09
IIIC	6 (3.2)	4 (6.3)	2 (1.6)
IVA	58 (30.5)	21 (33.3)	37 (29.1)
IVB	100 (52.6)	30 (47.6)	70 (55.1)
Postoperative recurrence	22 (11.6)	5 (8.0)	17 (13.4)
Histology
Adeno	158 (83.2)	39 (61.9)	119 (93.7)	< 0.001
Others	32 (16.8)	24 (38.1)	8 (6.3)
LCNEC	2 (1.0)	0	2 (1.6)
Pleomorphic carcinoma	4 (2.1)	4 (6.4)	0
NOS	26 (13.7)	20 (31.7)	6 (4.7)
PD-L1 TPS (%)
1-25	53 (27.9)	17 (27.0)	36 (28.3)	0.86
26-49	137 (72.1)	46 (73.0)	91 (71.7)
Liver metastasis	17 (9.0)	6 (9.5)	11 (8.7)	> 0.99
Brain metastasis	38 (20.2)	9 (14.5)	29 (23.0)	0.27
Treatment regimen
Pembro/CDDP or CBDCA/PEM	95 (49.7)	23 (36.5)	72 (56.3)
Pembro/CBDCA/PTX or nab-PTX	13 (6.9)	10 (15.9)	3 (2.3)
Atezo/CBDCA/PTX/BEV	26 (13.6)	10 (15.9)	16 (12.5)
Atezo/CBDCA/nab-PTX	15 (7.9)	7 (11.1)	8 (6.3)
Atezo/CBDCA/PEM	6 (3.1)	2 (3.2)	4 (3.1)
Nivo/IPI/Chemotherapy	31 (16.3)	11 (17.5)	20 (15.6)
Others	4 (2.1)	0	4 (3.1)

Values are presented as median (range) or number (%). Atezo, atezolizumab; BEV, bevacizumab; CBDCA, carboplatin; CDDP, cisplatin; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, ipilimumab; LCNEC; Large cell neuroendocrine carcinoma; Nivo, nivolumab; NOS, not otherwise specified; PD-L1, programmed cell death ligand 1; PEM, pemetrexed; PTX, paclitaxel; Pembro, pembrolizumab; TPS, tumor proportion score; TTF-1, thyroid transcription factor-1.

Table 3.

Predictive factors for progression free survival and overall survival in the chemotherapy cohort

Covariate	Crude HR	95% CI	p-value	Adjusted HR^a)	95% CI	p-value
Predictors of PFS in the chemotherapy cohort
TTF-1 (positive vs. negative)	0.62	0.40-0.97	0.03	0.58	0.36-0.93	0.02
Sex (men vs. women)	1.08	0.65-1.79	0.77	1.15	0.68-1.95	0.61
ECOG PS (PS 0-1 vs. PS ≥ 2)	0.52	0.25-1.09	0.08	0.41	0.19-0.88	0.02
Histology (adenocarcinoma vs. others)	0.74	0.45-1.23	0.25	0.75	0.44-1.27	0.28
Predictors of OS in the chemotherapy cohort
TTF-1 (positive vs. negative)	0.52	0.32-0.84	0.008	0.61	0.37-1.03	0.06
Sex (men vs. women)	1.09	0.62-1.92	0.76	1.05	0.59-1.86	0.88
ECOG-PS (PS 0-1 vs. PS ≥ 2)	0.61	0.30-1.25	0.18	0.66	0.32-1.35	0.25
Histology (adenocarcinoma vs. others)	0.51	0.30-0.85	0.009	0.60	0.35-1.04	0.07

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; TTF-1, thyroid transcription factor-1.

^a) HR for TTF-1 was adjusted for sex, ECOG PS, and histology.

Table 4.

Predictive factors for progression free survival and overall survival in the chemoimmunotherapy cohort

Covariate	Crude HR	95% CI	p-value	Adjusted HR^a)	95% CI	p-value
Predictors of PFS in the chemoimmunotherapy cohort
TTF-1 (positive vs. negative)	0.90	0.63-1.29	0.57	0.87	0.57-1.30	0.50
Sex (men vs. women)	1.01	0.65-1.56	0.96	0.98	0.63-1.53	0.93
ECOG PS (PS 0-1 vs. PS ≥ 2)	0.53	0.27-1.00	0.052	0.51	0.27-0.98	0.04
Histology (adenocarcinoma vs. others)	0.96	0.62-1.50	0.87	0.99	0.60-1.64	0.98
Predictors of OS in the chemoimmunotherapy cohort
TTF-1 (positive vs. negative)	0.71	0.47-1.06	0.09	0.79	0.50-1.25	0.31
Sex (men vs. women)	1.25	0.74-2.10	0.41	1.10	0.64-1.89	0.72
ECOG PS (PS 0-1 vs. PS ≥ 2)	0.81	0.38-1.75	0.59	0.72	0.33-1.58	0.42
Histology (adenocarcinoma vs. others)	0.63	0.39-1.03	0.06	0.72	0.41-1.23	0.23

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; TTF-1, thyroid transcription factor-1.

^a) HR for TTF-1 was adjusted for sex, ECOG PS, and histology.

REFERENCES

1. Pelosi G, Scarpa A, Forest F, Sonzogni A. The impact of immunohistochemistry on the classification of lung tumors. Expert Rev Respir Med. 2016;10:1105–21. Article PubMed
2. Khoor A, Whitsett JA, Stahlman MT, Olson SJ, Cagle PT. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol. 1999;30:695–700. Article PubMed
3. Di Loreto C, Di Lauro V, Puglisi F, Damante G, Fabbro D, Beltrami CA. Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma. J Clin Pathol. 1997;50:30–2. Article PubMed PMC
4. Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology. 2000;36:8–16. Article PubMed PDF
5. Zhang Y, Wang R, Li Y, Pan Y, Hu H, Zhang Y, et al. Negative thyroid transcription factor 1 expression defines an unfavorable subgroup of lung adenocarcinomas. J Thorac Oncol. 2015;10:1444–50. Article PubMed
6. Frost N, Zhamurashvili T, von Laffert M, Klauschen F, Ruwwe-Glosenkamp C, Raspe M, et al. Pemetrexed-based chemotherapy is inferior to pemetrexed-free regimens in thyroid transcription factor 1 (TTF-1)-negative, EGFR/ALK-negative lung adenocarcinoma: a propensity score matched pairs analysis. Clin Lung Cancer. 2020;21:e607–21. Article PubMed
7. Takeuchi A, Oguri T, Yamashita Y, Sone K, Fukuda S, Takakuwa O, et al. Value of TTF-1 expression in non-squamous non-small-cell lung cancer for assessing docetaxel monotherapy after chemotherapy failure. Mol Clin Oncol. 2020;13:9.Article PubMed PMC
8. Qian HH, Xu TS, Cai XQ, Ji TL, Guo HX. Prognostic value of TTF-1 expression in patients with non-small cell lung cancer: a meta-analysis. Clin Chim Acta. 2015;451:208–14. Article PubMed
9. Schilsky JB, Ni A, Ahn L, Datta S, Travis WD, Kris MG, et al. Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. Lung Cancer. 2017;108:205–11. Article PubMed
10. Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol. 2009;27:271–8. Article PubMed
11. Kim JH, Kim HS, Kim BJ, Han B, Choi DR, Kwon JH. Prognostic impact of TTF-1 expression in non-squamous non-small-cell lung cancer: a meta-analysis. J Cancer. 2018;9:4279–86. Article PubMed PMC
12. Saad RS, Liu YL, Han H, Landreneau RJ, Silverman JF. Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Hum Pathol. 2004;35:3–7. Article PubMed
13. Li X, Yin L, Zhao Y, He M, Qi Q, Sun Y, et al. The prognostic effect of TTF-1 expression in the Chinese population of patients with advanced lung adenocarcinomas. Transl Lung Cancer Res. 2020;9:82–9. Article PubMed PMC
14. Nakao A, Inoue H, Ikeuchi N, Igata F, Aoyama T, Hamasaki M, et al. Impact of results of TTF-1 immunostaining on efficacy of platinum-doublet chemotherapy in Japanese patients with nonsquamous non-small-cell lung cancer. J Clin Med. 2022;12:137.Article PubMed PMC
15. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8. Article PubMed PDF
16. Sun JM, Han J, Ahn JS, Park K, Ahn MJ. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol. 2011;6:1392–9. Article PubMed
17. Du B, Shim JS. Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules. 2016;21:965.Article PubMed PMC
18. Saito RA, Watabe T, Horiguchi K, Kohyama T, Saitoh M, Nagase T, et al. Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells. Cancer Res. 2009;69:2783–91. PubMed
19. Terashima Y, Matsumoto M, Iida H, Takashima S, Fukuizumi A, Takeuchi S, et al. Predictive impact of diffuse positivity for TTF-1 expression in patients treated with platinum-doublet chemotherapy plus immune checkpoint inhibitors for advanced nonsquamous NSCLC. JTO Clin Res Rep. 2023;4:100578.Article PubMed PMC
20. Nakahama K, Kaneda H, Osawa M, Izumi M, Yoshimoto N, Sugimoto A, et al. Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma. Thorac Cancer. 2022;13:2309–17. PubMed PMC
21. Iso H, Hisakane K, Mikami E, Suzuki T, Matsuki S, Atsumi K, et al. Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer. Transl Lung Cancer Res. 2023;12:1850–61. Article PubMed PMC
22. Ibusuki R, Yoneshima Y, Hashisako M, Matsuo N, Harada T, Tsuchiya-Kawano Y, et al. Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer. Transl Lung Cancer Res. 2022;11:2208–15. Article PubMed PMC
23. Okauchi S, Miyazaki K, Shiozawa T, Satoh H, Hizawa N. Relationship between TTF-1 expression and PFS of pemetrexed-containing chemotherapy in non-squamous-NSCLC patients with and without driver genes. Cancer Diagn Progn. 2023;3:53–60. Article PubMed PMC
24. Galland L, Le Page AL, Lecuelle J, Bibeau F, Oulkhouir Y, Derangere V, et al. Prognostic value of thyroid transcription factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1. Oncoimmunology. 2021;10:1957603.Article PubMed PMC
25. Katayama Y, Yamada T, Morimoto K, Fujii H, Morita S, Tanimura K, et al. TTF-1 expression and clinical outcomes of combined chemoimmunotherapy in patients with advanced lung adenocarcinoma: a prospective observational study. JTO Clin Res Rep. 2023;4:100494.Article PubMed PMC
26. Yvorel V, Patoir A, Casteillo F, Tissot C, Fournel P, Stachowicz ML, et al. PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis. PLoS One. 2017;12:e0180346Article PubMed PMC
27. Yu S, Jia M, Li Y, Sun PL, Gao H. Differential expression of PD-L1 in central and peripheral and TTF1-positive and -negative small-cell lung cancer. Front Med (Lausanne). 2020;7:621838.Article PubMed
28. Nishioka N, Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, et al. Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study. Front Immunol. 2024;15:1399889.Article PubMed PMC

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non–Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study

Cancer Res Treat. 2025;57(2):412-421. Published online October 25, 2024

DOI: https://doi.org/10.4143/crt.2024.748

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Fig. 1. Comparison of treatment efficacy between thyroid transcription factor-1 (TTF-1)–positive and negative groups in the chemotherapy and chemoimmunotherapy cohorts. Kaplan-Meier curves for progression-free survival (PFS) (A) and overall survival (OS) (B) in the chemotherapy cohorts. Kaplan-Meier curves for PFS (C) and OS (D) in the chemoimmunotherapy cohort. CI, confidence interval.

Fig. 2. Comparison of overall survival (OS) between pemetrexed (PEM)-based and non-PEM–based regimens within the chemotherapy and chemoimmunotherapy cohorts stratified by thyroid transcription factor-1 (TTF-1) expression status. We compared the OS between the PEM-based and non-PEM–based regimen groups in the chemotherapy and chemotherapy cohorts stratified by TTF-1 expression status. Kaplan-Meier curves are shown for the chemotherapy (A) and chemoimmunotherapy (B) groups in the TTF-1–positive population and for the chemotherapy (C) and chemoimmunotherapy (D) groups in the TTF-1–negative population. CI, confidence interval.

Fig. 1.

Fig. 2.

Characteristic	Total (n=93)	TTF-1–negative (n=40)	TTF-1–positive (n=53)	p-value
Age (yr)	68 (39-81)	70.5 (45-81)	66 (39-79)	0.06
Sex
Male	71 (76.3)	32 (80.0)	39 (73.6)	0.62
Female	22 (23.7)	8 (20.0)	14 (26.4)
ECOG PS
0-1	82 (88.2)	34 (85.0)	48 (90.6)	0.52
≥ 2	11 (11.8)	6 (15.0)	5 (9.4)
Stage
IIIB	4 (4.3)	1 (2.5)	3 (5.7)	0.24
IIIC	6 (6.5)	4 (10.0)	2 (3.8)
IVA	35 (37.6)	13 (32.5)	22 (41.5)
IVB	32 (34.4)	17 (42.5)	15 (28.2)
IVC	1 (1.1)	1 (2.5)	0
Postoperative recurrence	15 (16.1)	4 (10.0)	11 (20.8)
Histology
Adeno	68 (73.1)	24 (60.0)	44 (83.0)	0.02
Others	25 (26.9)	16 (40.0)	9 (17.0)
LCNEC	4 (4.3)	4 (10.0)	0
Pleomorphic carcinoma	0	0	0
NOS	21 (22.6)	12 (30.0)	9 (17.0)
PD-L1 TPS (%)
1-25	29 (31.2)	12 (30.0)	17 (32.1)	0.82
26-49	64 (68.8)	28 (72.0)	36 (67.9)
Liver metastasis	11 (11.8)	8 (20.0)	3 (5.7)	0.05
Brain metastasis	15 (16.1)	7 (17.5)	8 (15.1)	0.88
Treatment regimen
CBDCA/PTX or nab-PTX	31 (33.3)	17 (42.5)	14 (26.4)
CDDP or CBDCA/PTX/BEV	1 (1.1)	1 (2.5)	0
CDDP or CBDCA/PEM	30 (32.3)	11 (27.5)	19 (35.8)
CDDP or CBDCA/PEM/BEV	24 (25.8)	8 (20.0)	16 (30.2)
CDDP or CBDCA/S-1	6 (6.4)	2 (5.0)	4 (7.5)
CDDP/DTX	1 (1.1)	1 (2.5)	0

Characteristic	Total (n=190)	TTF-1–negative (n=63)	TTF-1–positive (n=127)	p-value
Age (yr)	69 (36-85)	69 (37-78)	68 (36-85)	0.64
Sex
Male	151 (79.5)	55 (87.3)	96 (75.6)	0.09
Female	39 (20.5)	8 (12.7)	31 (24.4)
ECOG PS
0-1	178 (93.7)	61 (96.8)	117 (92.1)	0.34
≥ 2	12 (6.3)	2 (3.2)	10 (7.9)
Stage
IIIB	4 (2.1)	3 (4.8)	1 (0.8)	0.09
IIIC	6 (3.2)	4 (6.3)	2 (1.6)
IVA	58 (30.5)	21 (33.3)	37 (29.1)
IVB	100 (52.6)	30 (47.6)	70 (55.1)
Postoperative recurrence	22 (11.6)	5 (8.0)	17 (13.4)
Histology
Adeno	158 (83.2)	39 (61.9)	119 (93.7)	< 0.001
Others	32 (16.8)	24 (38.1)	8 (6.3)
LCNEC	2 (1.0)	0	2 (1.6)
Pleomorphic carcinoma	4 (2.1)	4 (6.4)	0
NOS	26 (13.7)	20 (31.7)	6 (4.7)
PD-L1 TPS (%)
1-25	53 (27.9)	17 (27.0)	36 (28.3)	0.86
26-49	137 (72.1)	46 (73.0)	91 (71.7)
Liver metastasis	17 (9.0)	6 (9.5)	11 (8.7)	> 0.99
Brain metastasis	38 (20.2)	9 (14.5)	29 (23.0)	0.27
Treatment regimen
Pembro/CDDP or CBDCA/PEM	95 (49.7)	23 (36.5)	72 (56.3)
Pembro/CBDCA/PTX or nab-PTX	13 (6.9)	10 (15.9)	3 (2.3)
Atezo/CBDCA/PTX/BEV	26 (13.6)	10 (15.9)	16 (12.5)
Atezo/CBDCA/nab-PTX	15 (7.9)	7 (11.1)	8 (6.3)
Atezo/CBDCA/PEM	6 (3.1)	2 (3.2)	4 (3.1)
Nivo/IPI/Chemotherapy	31 (16.3)	11 (17.5)	20 (15.6)
Others	4 (2.1)	0	4 (3.1)

Covariate	Crude HR	95% CI	p-value	Adjusted HR^a)	95% CI	p-value
Predictors of PFS in the chemotherapy cohort
TTF-1 (positive vs. negative)	0.62	0.40-0.97	0.03	0.58	0.36-0.93	0.02
Sex (men vs. women)	1.08	0.65-1.79	0.77	1.15	0.68-1.95	0.61
ECOG PS (PS 0-1 vs. PS ≥ 2)	0.52	0.25-1.09	0.08	0.41	0.19-0.88	0.02
Histology (adenocarcinoma vs. others)	0.74	0.45-1.23	0.25	0.75	0.44-1.27	0.28
Predictors of OS in the chemotherapy cohort
TTF-1 (positive vs. negative)	0.52	0.32-0.84	0.008	0.61	0.37-1.03	0.06
Sex (men vs. women)	1.09	0.62-1.92	0.76	1.05	0.59-1.86	0.88
ECOG-PS (PS 0-1 vs. PS ≥ 2)	0.61	0.30-1.25	0.18	0.66	0.32-1.35	0.25
Histology (adenocarcinoma vs. others)	0.51	0.30-0.85	0.009	0.60	0.35-1.04	0.07

Covariate	Crude HR	95% CI	p-value	Adjusted HR^a)	95% CI	p-value
Predictors of PFS in the chemoimmunotherapy cohort
TTF-1 (positive vs. negative)	0.90	0.63-1.29	0.57	0.87	0.57-1.30	0.50
Sex (men vs. women)	1.01	0.65-1.56	0.96	0.98	0.63-1.53	0.93
ECOG PS (PS 0-1 vs. PS ≥ 2)	0.53	0.27-1.00	0.052	0.51	0.27-0.98	0.04
Histology (adenocarcinoma vs. others)	0.96	0.62-1.50	0.87	0.99	0.60-1.64	0.98
Predictors of OS in the chemoimmunotherapy cohort
TTF-1 (positive vs. negative)	0.71	0.47-1.06	0.09	0.79	0.50-1.25	0.31
Sex (men vs. women)	1.25	0.74-2.10	0.41	1.10	0.64-1.89	0.72
ECOG PS (PS 0-1 vs. PS ≥ 2)	0.81	0.38-1.75	0.59	0.72	0.33-1.58	0.42
Histology (adenocarcinoma vs. others)	0.63	0.39-1.03	0.06	0.72	0.41-1.23	0.23

Table 1. Patient characteristics: chemotherapy cohort

Table 2. Patient characteristics: chemoimmunotherapy cohort

Table 3. Predictive factors for progression free survival and overall survival in the chemotherapy cohort

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; TTF-1, thyroid transcription factor-1.

HR for TTF-1 was adjusted for sex, ECOG PS, and histology.

Table 4. Predictive factors for progression free survival and overall survival in the chemoimmunotherapy cohort

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; TTF-1, thyroid transcription factor-1.